key: cord-0737841-tmavzkfm
authors: Conley, Thomas E; Probert, Chris; Subramanian, Sreedhar
title: Prevalence of COVID-19 Symptoms among Inflammatory Bowel Disease Patients Treated with Biological Agents
date: 2020-09-11
journal: J Crohns Colitis
DOI: 10.1093/ecco-jcc/jjaa187
sha: 912fdfc6b1162b33779dc3c0a411d1a2c482756e
doc_id: 737841
cord_uid: tmavzkfm

nan

A c c e p t e d M a n u s c r i p t

We read with interest the recommendations from the ECCO-COVID taskforce on the management of inflammatory bowel disease patients during the Covid-19 pandemic in which they recommend continuation of biologic and immunomodulatory therapy 1 . Further reassuring data from the international SECURE-IBD registry 2 on the outcomes of Covid-19 among IBD patients treated with anti-tumour necrosis factor (TNF) agents lend support to the ECCO recommendations. Whilst the data from the SECURE-IBD registry for outcomes of Covid-19 among biologics treated patients are reassuring, they rely on physician reporting and prone to selection bias. There is a paucity of data on the prevalence of Covid-19 symptoms among an unselected cohort of IBD patients treated with biologics. We conducted a survey on the prevalence of Covid-19 symptoms among consecutive IBD patients treated with biologics attending our infusion unit for administration of intravenous or subcutaneous biologics during the calendar period 24/02/2020 to 10/07/2020 (patient characteristics, Table 1 ). Patients were asked to report if they had symptoms suggestive of Covid-19 as described previously 3 (fever, chills, severe tiredness, sore throat, cough, shortness of breath, headache, anosmia or ageusia, and new onset nausea, vomiting, or diarrhoea) during the preceding three months and if they had been tested or hospitalized for Covid-19. We considered presence of fever, cough with or without ansomia to represent Covid-19 symptoms. Categorical variables are summarized as frequency (%) and continuous variables as median. We compared variables between UC and CD using Fisher's Exact test.

Of the 203 patients who responded, 105 (52%) had CD and 98 (48%) had UC. Baseline characteristics were comparable between UC and CD apart from a higher proportion of women among CD patients (84.8% vs 51.1%, P<0.001) and a higher rate of corticosteroid use among UC patients (12.3% vs 4.8%, p=0.075). Of the entire cohort, 101 (46.6%) patients were on a concomitant immunomodulator. A large proportion reported following shielding (n=114, 56.2%) or following social isolation (n=40, 19.7%), in keeping with recommendations from UK government.

The overall prevalence of typical Covid-19 symptoms was 28.6% among ulcerative colitis (UC) and 13.3% among Crohn's disease (CD) patients (P=0.009). None of the patients were hospitalized.

Though the prevalence of Covid-19 symptoms among this cohort is higher than that reported in the UK population, the figure is broadly consistent with putative infection rates reported from a modelling study in the UK 4 . The higher prevalence of Covid-19 symptoms in UC is intriguing and largely explained by gender differences and concomitant steroid therapy. The main limitation of our study is the lack of virological confirmation of Covid-19 illness. Reassuringly, none of the patients reported hospitalization or severe illness. Our findings provide further reassurance and add to emerging evidence 5 of favourable Covid-19 outcomes in this group of patients. M a n u s c r i p t 

Inflammatory bowel disease management during the COVID-19 outbreak: The 10 do's and don'ts from the ECCO-COVID Taskforce

But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry

Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study

A phased approach to unlocking during the COVID-19 pandemic-Lessons from trend analysis

Seroconversion of immunoglobulins to SARS-CoV2 in patients with inflammatory bowel disease patients treated by biologics

A c c e p t e d M a n u s c r i p t